StockData
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. (SLS) shareholders

SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$19.15+11.68 (+156.36%)

Close on Nov 17, 2026Market cap $3.87BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
36.5%
74M of 202M shares
Institutional holders
192
63 new, 27 sold out
Net institutional buying
20M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $100.81K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.15,872,6857.90%13G (passive) amendmentSep 30, 2026
State Street Corporation10,373,0745.10%13G (passive)Sep 30, 2026
Vanguard Capital Management9,666,2785.19%13G (passive)Jun 30, 2026
Moez Kassam
Joint filing with Anson Funds Management LP (8.30%), Anson Management GP LLC (8.30%) and 3 more
7,579,0958.30%13G (passive)Mar 31, 2025
Anson Advisors Inc.
Joint filing with Anson Funds Management LP (5.70%), Anson Management GP LLC (5.70%) and 3 more
6,032,9385.70%13G (passive)Sep 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SLSValueChange% of portfolio
BlackRock, Inc.15,070,3027.46%$222.44M+2,871,8920.00%
State Street Corp12,996,5586.44%$191.83M+4,600,2020.01%
Vanguard Capital Management LLC8,226,1054.07%$121.42M+700,1760.00%
Geode Capital Management, LLC4,884,1752.42%$72.11M+971,5690.00%
Anson Funds Management LP4,500,0002.23%$66.42MNew3.94%
Jones Financial Companies Lllp2,304,5611.14%$28.55M+629,4840.01%
Vanguard Portfolio Management LLC2,161,0991.07%$31.90M+698,2930.00%
Susquehanna International Group, Llp2,050,5971.02%$30.27M+1,653,5410.00%
Northern Trust Corp1,619,9280.80%$23.91M+343,9440.00%
Vanguard Fiduciary Trust Co1,335,1660.66%$19.71M+132,3270.00%
UBS Group AG1,252,7570.62%$18.49M+507,3380.00%
Morgan Stanley1,236,2610.61%$18.25M−100,0320.00%
Dagco, Inc.1,232,4330.61%$18.19M+203,6533.36%
Bnp Paribas Arbitrage, Snc1,072,0220.53%$15.82M+1,025,0060.01%
Bank Of America Corp /De/787,9490.39%$11.63M+146,2660.00%
Wellington Management Group Llp597,3090.30%$8.82M+252,5310.00%
Goldman Sachs Group Inc585,0350.29%$8.64M+29,1220.00%
Charles Schwab Investment Management Inc565,0080.28%$8.34M+84,4040.00%
Bank of New York Mellon Corp530,0250.26%$7.82M+51,6590.00%
Jane Street Group, LLC508,4290.25%$7.50MNew0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202619274M36.5%63 / 7826 / 2725M5M
Q1 202616054M26.7%67 / 5318 / 1631M4M
Q4 202511235M17.6%28 / 4919 / 911M9M
Q3 20259433M16.3%21 / 3118 / 59M3M
Q2 20257927M13.3%40 / 227 / 620M8M
Q1 20254514M7.1%18 / 183 / 48M0M
Q4 2024316M3.1%6 / 105 / 81M0M
Q3 2024335M2.7%9 / 105 / 42M0M
Q2 2024304M2.0%9 / 122 / 91M5M
Q1 2024308M3.8%7 / 86 / 85M1M
Q4 2023314M1.7%8 / 133 / 52M1M
Q3 2023283M1.4%5 / 96 / 20M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

113 funds held SLS in Q2 2026, 79% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of SLSValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF8,654,7204.29%$127.74M1.19%Jun 30, 2026
Vanguard Total Stock Market Index Fund5,906,9222.93%$87.19M0.00%Jun 30, 2026
iShares Russell 2000 ETF4,928,3352.44%$72.74M0.09%Jun 30, 2026
Vanguard Extended Market Index Fund2,134,8371.06%$31.51M0.03%Jun 30, 2026
Fidelity Small Cap Index Fund2,063,9631.02%$20.66M0.06%Jul 31, 2026
iShares Russell 2000 Growth ETF1,742,1140.86%$25.71M0.17%Jun 30, 2026
Vanguard Russell 2000 Index Fund883,0260.44%$8.22M0.05%May 31, 2026
Fidelity Extended Market Index Fund881,2400.44%$8.20M0.02%May 31, 2026
iShares Micro-Cap ETF632,1840.31%$9.33M0.61%Jun 30, 2026
Vanguard U.S. Momentum Factor ETF604,6120.30%$5.63M0.31%May 31, 2026
Schwab Small-Cap Index Fund458,8890.23%$4.59M0.06%Jul 31, 2026
Master Small Cap Index Series343,2710.17%$5.07M0.08%Jun 30, 2026
Fidelity Total Market Index Fund318,6150.16%$2.97M0.00%May 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares293,2500.15%$2.94M0.59%Jul 31, 2026
Invesco Dorsey Wright SmallCap Momentum ETF274,4590.14%$2.56M0.61%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Angelos M. StergiouPresident and CEO, Director1,976,6040.98%Jun 18, 2026
John Thomas BurnsCFO609,2540.30%Jan 9, 2026
Dragan CicicSVP, Chief Development Officer557,8050.28%Jan 9, 2026
David A. ScheinbergDirector73,0820.04%Jan 9, 2026
Nostrand Robert L. VanDirector82,9000.04%Jan 9, 2026
Katherine Bach KalinDirector154,4000.08%Jan 9, 2026
John VarianDirector72,9000.04%Jan 9, 2026
Jane WasmanDirector92,9000.05%Jan 9, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Angelos M. Stergiou
President and CEO, Director
Jun 16, 2026Award+1,065,000––1,759,183
Dragan Cicic
SVP, Chief Development Officer
Jan 7, 2026Award+300,000––557,805
David A. Scheinberg
Director
Jan 7, 2026Award+50,000––73,082
John Thomas Burns
CFO
Jan 7, 2026Award+300,000––554,327
John Varian
Director
Jan 7, 2026Award+50,000––72,900
Nostrand Robert L. Van
Director
Jan 7, 2026Award+50,000––82,900
Katherine Bach Kalin
Director
Jan 7, 2026Award+50,000––154,400
Jane Wasman
Director
Jan 7, 2026Award+50,000––92,900
John Thomas Burns
CFO
Dec 3, 2025Other−58,592$1.50$87.89K254,327
Dragan Cicic
SVP, Chief Development Officer
Dec 3, 2025Other−63,800$1.50$95.70K257,805
Angelos M. Stergiou
President and CEO, Director
Dec 3, 2025Other−187,066$1.50$280.60K686,966
Katherine Bach Kalin
Director
Nov 19, 2025Buy+63,400$1.59$100.81K104,400
Nostrand Robert L. Van
Director
Jun 12, 2025Buy+10,000$1.48$14.80K20,400
Jane Wasman
Director
May 30, 2025Buy+20,000$1.69$33.80K30,400
Katherine Bach Kalin
Director
May 22, 2025Buy+20,000$1.80$36.00K41,000
John Varian
Director
Jan 10, 2025Award+12,500––22,900
Jane Wasman
Director
Jan 10, 2025Award+12,500––22,900
Dragan Cicic
SVP, Chief Development Officer
Jan 10, 2025Award+113,000––228,328
Dragan Cicic
SVP, Chief Development Officer
Jan 10, 2025Award+81,300––309,628
Angelos M. Stergiou
President and CEO, Director
Jan 10, 2025Award+257,000––615,132
Angelos M. Stergiou
President and CEO, Director
Jan 10, 2025Award+243,900––859,032
Katherine Bach Kalin
Director
Jan 10, 2025Award+12,500––21,000
John Thomas Burns
CFO
Jan 10, 2025Award+81,300––299,062
John Thomas Burns
CFO
Jan 10, 2025Award+113,000––217,762
Nostrand Robert L. Van
Director
Jan 10, 2025Award+12,500––22,900
David A. Scheinberg
Director
Jan 10, 2025Award+12,500––23,082
John Thomas Burns
CFO
Dec 4, 2024Other−7,165$1.13$8.10K104,762
Dragan Cicic
SVP, Chief Development Officer
Dec 4, 2024Other−8,256$1.13$9.33K115,328
Angelos M. Stergiou
President and CEO, Director
Dec 4, 2024Other−28,289$1.13$31.97K358,132
Barbara A. Wood
EVP, Gen. Counsel, Corp. Sec.
Jan 22, 2024Award+35,000––117,225
Angelos M. Stergiou
President and CEO, Director
Jan 22, 2024Award+159,000––376,421
Robert Francomano
Chief Commercial Officer
Jan 22, 2024Award+20,000––40,918
John Thomas Burns
CFO
Jan 22, 2024Award+47,000––101,927
Nostrand Robert L. Van
Director
Jan 22, 2024Award+6,000––10,400
John Varian
Director
Jan 22, 2024Award+6,000––10,400
Jane Wasman
Director
Jan 22, 2024Award+6,000––10,400
David A. Scheinberg
Director
Jan 22, 2024Award+6,000––10,582
Katherine Bach Kalin
Director
Jan 22, 2024Award+6,000––8,500
Barbara A. Wood
EVP, Gen. Counsel, Corp. Sec.
Dec 6, 2023Other−4,119$1.08$4.45K82,225
John Thomas Burns
CFO
Dec 6, 2023Other−2,929$1.08$3.16K54,927
Robert Francomano
Chief Commercial Officer
Dec 6, 2023Other−1,082$1.08$1.17K20,918
Angelos M. Stergiou
President and CEO, Director
Dec 6, 2023Other−12,268$1.08$13.25K217,421
Robert Francomano
Chief Commercial Officer
Feb 2, 2023Award+12,000––12,000
David A. Scheinberg
Director
Feb 2, 2023Award+2,500––4,582
John Thomas Burns
CFO
Feb 2, 2023Award+20,000––49,347
Angelos M. Stergiou
President and CEO, Director
Feb 2, 2023Award+58,000––219,689
Barbara A. Wood
EVP, Gen. Counsel, Corp. Sec.
Feb 2, 2023Award+20,000––76,344
Jane Wasman
Director
Feb 2, 2023Award+2,500––4,400
Nostrand Robert L. Van
Director
Feb 2, 2023Award+2,500––4,400
Katherine Bach Kalin
Director
Feb 2, 2023Award+2,500––2,500
John Varian
Director
Feb 2, 2023Award+2,500––4,400
Barbara A. Wood
EVP, Gen. Counsel, Corp. Sec.
Dec 5, 2022Sale−2,153$2.59$5.58K56,344
Angelos M. Stergiou
President and CEO, Director
Dec 5, 2022Sale−6,494$2.61$16.95K161,689
John Thomas Burns
Senior VP, Finance & CAO
Dec 5, 2022Sale−1,159$2.59$3.00K29,347
John Varian
Director
Jan 31, 2022Award+1,900––1,900
Nostrand Robert L. Van
Director
Jan 31, 2022Award+1,900––1,900
John Thomas Burns
Senior VP, Finance & CAO
Jan 31, 2022Award+9,600––27,244
David A. Scheinberg
Director
Jan 31, 2022Award+1,900––2,082
Angelos M. Stergiou
President and CEO, Director
Jan 31, 2022Award+44,000––165,167
Jane Wasman
Director
Jan 31, 2022Award+1,900––1,900

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
28.80%
57M shares short
Days to cover
6.7
At 9M shares a day
Change since last report
+6.3%
From 54M shares
Short volume, 20 days
57.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of SELLAS Life Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 403,160 shares on Sep 1, 2026 over the last 90 days.

See a number that looks wrong?